Dick's Sporting Goods (DKS) Makes Analysts Sweat Ahead of $2.4B Foot Locker Deal
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TD Cowen analyst John Kernan kept a Hold rating on the stock, despite hiking its price target from $205 to $231.
Running Risks
Kernan said the Hold rating was 'based off unknown risks associated with the Foot Locker business.'
This is in reference to the $24 a share offer made for Foot Locker in May this year. It was, at that point, an 86% premium to the stock's last closing price.
The DKS share price initially suffered post-announcement, but has bounced back since – see below.
That dip was mostly down to wariness over the health of the Foot Locker business. It has struggled since the Covid-19 pandemic shut down its stores or forced them to operate at reduced capacity. Prior to news of the acquisition, FL stock had lost about 40% of its value this year and was down nearly 50% over the past five years.
Other analysts have previously warned that running an athletic specialty retailer that focuses on fashion lifestyle consumers, and operates smaller stores, many of which are in malls or in urban street locations, is not within the 'core competencies' of Dick's Sporting Goods.
The deal is not only making investors sweat.
Senator Elizabeth Warren has recently called on the Federal Trade Commission and Department of Justice to consider blocking the deal, writing in a letter to the agencies that the merger could cut jobs, raise prices and reduce competition.
Deal Drivers
However, Kernan is, despite his uncertainty, relatively optimistic. He said that one driver for the deal, which is expected to close in the second half of this year, is that sportswear giant Nike (NKE) has a vested interest in seeing the deal work.
'The cost and procurement synergies total $100 million to $125 million and investors seem to be warming to these figures in our conversations. Headcount reductions and store rationalization are also likely,' Kernan said.
Kernan added that if Foot Locker can return to a 4% to 5% EBIT margin, Dick's has a path to meaningful earnings per share, see below, and free cash flow growth. Indeed, he sees Dick's posting EPS of $16.47 in 2027 versus the consensus of $16.26.
For full year 2026, he said Dick's should see a 3% lift in same-store sales.
Is DKS a Good Stock to Buy Now?
On TipRanks, DKS has a Moderate Buy consensus based on 8 Buy and 10 Hold ratings. Its highest price target is $247. DKS stock's consensus price target is $216.57, implying a 3.3% downside.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
AM Best Affirms Credit Ratings of Saudi Arabian Insurance Company B.S.C. (c)
LONDON--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating of B+ (Good) and the Long-Term Issuer Credit Rating of 'bbb-' (Good) of Saudi Arabian Insurance Company B.S.C. (c) (Damana) (Bahrain). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Damana's balance sheet strength, which AM Best assesses as very strong, as well as its marginal operating performance, limited business profile and marginal enterprise risk management. The ratings also factor in the neutral impact from Damana's ultimate parent, Mawarid Holding Company. Damana's balance sheet strength assessment is underpinned by its risk-adjusted capitalisation, which was at the very strong level as at year-end 2023, as measured by Best's Capital Adequacy Ratio (BCAR). AM Best expects BCAR scores to have recovered substantially to the strongest level in 2024, and year-to-date 2025, following the disposal of a large equity holding. Damana's investment portfolio is now largely conservative and consists mostly of cash and deposits. An offsetting factor to the assessment is the company's reliance on reinsurance for high-value risks, which is a common trait in the region; however, credit risk is minimised by a panel of sound credit quality. Damana's operating performance is assessed as marginal. The company has struggled with negative underwriting results for several years due to high expenses arising from its operating model and substantially reduced business scale. Loss ratios have also been affected by material events, such as the COVID-19 pandemic and the 2024 Dubai floods. Year-on-year improvements in the expense ratio have led to reductions in combined ratios from their peak of 148% in 2021, though underwriting operations remain unprofitable. Over the medium term and as the business continues to grow into its expense base, underwriting results are expected to trend towards profitability. Investment returns supplement performance, with Damana generating solid returns from its conservatively invested portfolio. Damana has seen business volumes steadily increase year-on-year since it suffered a reduction of revenues in 2021, following regulatory restrictions imposed by the Central Bank of Bahrain on the company's operations within that country. AM Best expects this trend in revenue growth to continue into the next few years, supported by Damana's renewed focus on new lines of business beyond its core lines of motor and medical. This strategy does expose Damana to execution risk given the challenging and competitive conditions in its core markets of Bahrain, the United Arab Emirates, Oman and Kuwait. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
Yahoo
17 minutes ago
- Yahoo
Avis Budget double-downgraded: 'Fundamentals don't support valuation'
-- Bank of America cut its rating for Avis Budget (NASDAQ:CAR) Group to Underperform from Buy in a note on Wednesday, warning that the company's fundamentals and industry backdrop do not justify its current share price. 'We think that CAR fundamentals and the macro environment don't support the current stock price, which significantly outperformed the market in June,' BofA analysts wrote in a note to clients. The firm lowered its price target to $113 for the stock, down from $120. BofA flagged 'pricing and demand pressures in the U.S. which negatively affects CAR's earnings power in 2H25/2026.' The analysts said a survey the bank conducted shows fewer consumers plan to increase travel spending in the next three months compared to 2024. 'This should translate into a soft pricing environment,' BofA wrote, adding that tariffs could further weaken demand in the second half. The bank acknowledged recent initiatives such as Avis First, aimed at the premium segment, and a fleet management partnership with Waymo. 'We see these developments as positives, and they speak to the fact that CAR is a strong operator. However, we don't expect these initiatives to have a significant effect on earnings in the near term,' the analysts said. Vehicle depreciation remains a swing factor. 'Although this is a potential tailwind, we believe that the effect may not be as large as thought,' BofA said, noting the current environment differs from the Covid period. The bank cut its 2025 and 2026 EBITDA estimates to $0.9 billion and $1.03 billion, respectively, and lowered its valuation multiple. 'We cut our PO to $113 from $120, valued on 7.5x EV/EBITDA 2026,' the analysts wrote Related articles Avis Budget double-downgraded: 'Fundamentals don't support valuation' If Powell goes, does Fed trust go with him? 7 Undervalued Stocks on the Rise With 50%+ Upside Potential
Yahoo
17 minutes ago
- Yahoo
BofA downgrades Novavax stock on vaccine uncertainty
-- Bank of America cut its rating on Novavax (NASDAQ:NVAX) to Underperform from Neutral and lowered its price objective to $7 from $9, saying recent gains in the shares have overrun a still uncertain outlook for the company's COVID-19 and flu vaccine programs. Analysts said that while Novavax has executed well on cost cutting and operational cleanup, they see limited revenue upside near term. They noted that commercialization of its COVID vaccine Nuvaxovid by partner Sanofi (NASDAQ:SNY) may be slow due to a restrictive U.S. label and fading pandemic demand. The bank also said new FDA guidelines could make it harder and costlier for Novavax to sign new partners for its combined COVID/flu vaccine program. BofA forecasts slowing overall revenue, estimating about $1 billion in 2025, slightly below the company's guidance. It expects longer-term COVID sales to taper as variant shifts require more studies, and cut its peak market share estimate for Nuvaxovid to 14% from 18%. The analysts said the company's vaccine platform still has potential but requires more external validation, with platform licensing or partnership deals representing the main upside risk to their view. COVID opportunity is largely priced in, according to analysts warning that consensus revenue estimates may still be too high for the coming two years. Novavax shares had risen recently as funding cuts hit mRNA competitors, but BofA said that tailwind now looks temporary Related articles BofA downgrades Novavax stock on vaccine uncertainty Victoria's Secret Exposed: The Warning Sign Behind the Stock's 52% Collapse Risks Rising? Smart Money Dodged 46%+ Drawdowns on These High-Flying Names Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
